• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Ardelyx Inc.

    2/12/25 5:58:54 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001815433
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ARDELYX, INC.
    SEC File Number
    001-36485
    Address of Issuer
    400 FIFTH AVE.
    SUITE 210
    WALTHAM
    MASSACHUSETTS
    02451
    Phone
    510-745-7047
    Name of Person for Whose Account the Securities are To Be Sold
    Blanks Robert
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    COMMON
    MORGAN STANLEY SMITH BARNEY LLC EXECUTIVE SERVICES
    200 W CIVIC CENTER DR - 4TH FLOOR
    SANDY � UT � 84070
    75000409765.2023690000002/12/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    COMMON02/12/2025STOCK OPTION EXERCISEISSUERCheckbox not checked7500002/12/2025COMPENSATION

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    ROBERT C BLANKS
    400 FIFTH AVE., SUITE 210,
    WALTHAM � MA � 02451
    RESTRICTED STOCK11/20/2024494123689.52

    144: Remarks and Signature

    Remarks
    Date of Notice
    02/12/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Robert Christian Blanks

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ARDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARDX

    DatePrice TargetRatingAnalyst
    5/2/2025$11.00Strong Buy → Outperform
    Raymond James
    3/7/2025Buy
    Ladenburg Thalmann
    3/4/2025$14.00Buy
    BTIG Research
    11/11/2024$11.00 → $5.50Buy → Neutral
    H.C. Wainwright
    7/2/2024$15.00 → $7.00Overweight → Neutral
    Piper Sandler
    4/5/2024$14.00Outperform
    Leerink Partners
    12/18/2023$12.00Strong Buy
    Raymond James
    9/7/2023$9.00Buy
    H.C. Wainwright
    More analyst ratings

    $ARDX
    Financials

    Live finance-specific insights

    See more
    • Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

      Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Ardelyx deliver

      5/1/25 4:01:51 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

      WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Inves

      4/17/25 8:00:56 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion Company ended FY 2024 with $250.1 million in cash, cash equivalents and investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended

      2/20/25 7:30:54 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XPHOZAH issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      10/20/23 4:37:52 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for XPHOZAH issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

      10/18/23 4:43:04 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for XPHOZA™ issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

      10/18/23 4:37:08 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      11/14/24 4:08:33 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      7/10/24 6:32:11 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      2/13/24 5:26:59 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ardelyx downgraded by Raymond James with a new price target

      Raymond James downgraded Ardelyx from Strong Buy to Outperform and set a new price target of $11.00

      5/2/25 8:06:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on Ardelyx

      Ladenburg Thalmann resumed coverage of Ardelyx with a rating of Buy

      3/7/25 8:02:22 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Ardelyx with a new price target

      BTIG Research initiated coverage of Ardelyx with a rating of Buy and set a new price target of $14.00

      3/4/25 7:19:29 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mott David M bought $1,610,936 worth of shares (381,377 units at $4.22), increasing direct ownership by 19% to 2,396,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:22:23 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Raab Michael sold $177,168 worth of shares (41,666 units at $4.25) and exercised 20,833 shares at a strike of $0.99, decreasing direct ownership by 1% to 1,594,754 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:14:10 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Raab Michael exercised 20,833 shares at a strike of $0.99 and sold $191,151 worth of shares (41,666 units at $4.59), decreasing direct ownership by 1% to 1,615,587 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      4/8/25 7:24:24 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mott David M bought $1,610,936 worth of shares (381,377 units at $4.22), increasing direct ownership by 19% to 2,396,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:22:23 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $388,738 worth of shares (77,729 units at $5.00), increasing direct ownership by 4% to 2,015,494 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      2/26/25 7:21:25 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $992,672 worth of shares (199,000 units at $4.99), increasing direct ownership by 11% to 1,937,765 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      1/22/25 5:25:52 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

      WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data supporting the company's first-in-class retainagogue, IBSRELA® (tenapanor), as well as results from the IBS in America 2024 supplemental survey, at the Digestive Disease Week Conference (DDW), now underway in San Diego. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults. "Ardelyx is committed to continuing to grow

      5/6/25 8:01:45 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

      Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Ardelyx deliver

      5/1/25 4:01:51 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company's board of directors. "We are thrilled to welcome Merdad to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical d

      4/29/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company's board of directors. "We are thrilled to welcome Merdad to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical d

      4/29/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

      WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te

      8/8/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

      WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to Ardelyx an extensive array of mergers and acquisitions, business development, strategy, finance and operational leadership expertise from leading biotechnology and global pharmaceutical companies.

      3/25/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    SEC Filings

    See more
    • SEC Form 144 filed by Ardelyx Inc.

      144 - ARDELYX, INC. (0001437402) (Subject)

      5/2/25 4:22:02 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ardelyx Inc.

      10-Q - ARDELYX, INC. (0001437402) (Filer)

      5/1/25 4:04:48 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARDELYX, INC. (0001437402) (Filer)

      5/1/25 4:03:36 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care